Monday, September 23, 2019
- 1:45pm-3:15pm
-
A phase IIa trial studying the safety and tolerability of IRL752 in patients with Parkinson’s disease dementia
Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
A pilot study of the feasibility and effects of table tennis training in Parkinson’s Disease
Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
A Protocol to Test the Effects of TDCS on Consolidation of Writing Practice in Parkinson’s Disease
Physical and Occupational Therapy · Les Muses Terrace, Level 3
- 1:45pm-3:15pm
-
A randomized clinical trial of multimodal balance training with rhythmical cues: effects on freezing of gait in Parkinson’s disease
Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
A randomized, placebo-controlled, double-blind clinical study in Japan of Opicapone treatment for Parkinson’s Disease -Comfort-PD Study part 1
Clinical Trials, Pharmacology and Treatment · Agora 3 West, Level 3
- 1:45pm-3:15pm
-
A recessive repeat expansion causes CANVAS and is a common cause of Late-Onset Ataxia
Ataxia · Les Muses, Level 3
- 1:45pm-3:15pm
-
A retrospective analysis of clinical and electrophysiological characteristics of patients with myoclonus
Myoclonus · Les Muses, Level 3
- 1:45pm-3:15pm
-
A review of interactive voice response systems in Parkinson’s Disease
Other · Agora 2 West, Level 2
- 1:45pm-3:15pm
-
A Robust and Rapid Method of PCR amplification To Confirm Triplet Repeat Disorders: Single-Step Blood Direct PCR
Ataxia · Les Muses, Level 3
- 1:45pm-3:15pm
-
A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease
Huntington’s Disease · Agora 3 West, Level 3
- «Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 75
- Next Page»